Medical devices, healthcare technology and the business of care
PMA approval · P240010

MI Cancer Seek

Caris Life Sciences · Decision date Nov 5, 2024

MEDTECHLEDGER EXPLANATIONP240010

What did the FDA approve?

The FDA decision dated 2024-11-05 is an approval (APPR) for MI Cancer Seek, submitted by Caris Life Sciences under PMA number P240010. No supplement type or supplement reason is provided, so the record does not establish this as a supplement to an earlier PMA; it describes the device scope directly. MI Cancer Seek is a next-generation sequencing-based in vitro diagnostic using total nucleic acid from formalin-fixed paraffin-embedded tumor tissue to detect single nucleotide variants and insertions and deletions in 228 genes, microsatellite instability, and tumor mutational burden in patients with previously diagnosed solid tumors, plus copy number amplification in one gene in patients with breast cancer.

The stated purpose is companion diagnostic use to identify patients who may benefit from the targeted therapies listed in Table 1, per approved therapeutic product labeling, and tumor mutational profiling by qualified healthcare professionals in accordance with professional oncology guidelines. The statement says genomic findings outside Table 1 are not prescriptive or conclusive for labeled use of any specific therapeutic product. This wording reports intended use; it does not itself demonstrate safety or clinical effectiveness. Table 1 is referenced but not reproduced in the supplied fields, and the specific gene for copy number amplification is unnamed, so those details are absent from the record.

FDA approval order statement

Approval order for MI Cancer Seek. MI Cancer Seek is a next-generation sequencing (NGS) based in vitro diagnostic (IVD) device using total nucleic acid (TNA) isolated from formalin-fixed paraffin-embedded (FFPE) tumor tissue specimens for the detection of single nucleotide variants (SNVs) and insertions and deletions (indels) in 228 genes, microsatellite instability (MSI), tumor mutational burden (TMB) in patients with previously diagnosed solid tumors, and copy number amplification (CNA) in one gene in patients with breast cancer. MI Cancer Seek is intended as a companion diagnostic to identify patients who may benefit from treatment with the targeted therapies listed in Table 1 below, in accordance with the approved therapeutic product labeling (see approval order for Table 1).Additionally, MI Cancer Seek is intended to provide tumor mutational profiling to be used by qualified healthcare professionals in accordance with professional oncology guidelines for cancer patients with previously diagnosed solid malignant neoplasms. Genomic findings other than those listed in Table 1 are not prescriptive or conclusive for labeled use of any specific therapeutic product.
Regulatory pathway
Original PMA
Clinical specialty
Medical Genetics
Decision date
Nov 5, 2024

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P240010
Regulatory pathway
Premarket approval application
Product code
PQP
Decision code
APPR
Decision date
Nov 5, 2024
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Next generation sequencing oncology panel, somatic or germline variant detection system.

Product code
PQP
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P240010 received

    Application receipt date recorded by FDA.

  2. P240010 · FDA decision

    APPR

Timeline entries are records held by MedtechLedger for P240010. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P240010

Product / regulatory recordCompanyPathwayDecision dateSource
MI Cancer SeekP240010/S007
Caris Life SciencesPMA supplementOct 16, 2026FDA

Explore the linked device profile

Other records with product code PQP

Product / regulatory recordCompanyPathwayDecision dateSource
Life Technologies CorporationPMA supplementNov 4, 2026FDA
xT CDxP210011/S006
Tempus AI, Inc.PMA supplementOct 23, 2026FDA
Foundation Medicine, Inc.PMA supplementSep 18, 2026FDA
Guardant360 CDxP200010/S029
Guardant Health, Inc.PMA supplementSep 18, 2026FDA
FoundationOne CDxP170019/S069
Foundation Medicine, Inc.PMA supplementSep 16, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Caris Life Sciences

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
4610 S. 44th Pl., Phoenix, AZ, 85040

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records